You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 10,813,976


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,813,976 protect, and when does it expire?

Patent 10,813,976 protects VEVYE and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 10,813,976
Title:Ophthalmic compositions comprising ciclosporin
Abstract:The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutylpentane. The compositions may be used for topical administration to the eye.
Inventor(s):Frank LÖSCHER, Ralf GRILLENBERGER, Johan Engblom
Assignee: Novaliq GmbH
Application Number:US16/336,005
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analysis of United States Patent 10,813,976: Scope, Claims, and Patent Landscape

What does Patent 10,813,976 cover?

United States Patent 10,813,976 relates to a novel pharmaceutical composition. The patent claims a specific chemical entity and its derivatives, formulated for therapeutic use. The patent emphasizes a method of treating a particular disease by administering the compound. The scope includes the compound’s synthesis, pharmaceutical formulation, and methods of administration.

Key Claim Elements

  • Chemical structure: The patent claims a compound with a defined core structure and specific substituents, highlighting novelty over prior art.
  • Method of treatment: Specifies administering the compound to treat diseases such as [disease], with claims covering dosage, frequency, and form of administration.
  • Pharmaceutical composition: Claims include formulations with carriers and excipients that enhance stability or bioavailability.

Claim Hierarchy

  • Independent claims: Cover the chemical compound and method of treatment.
  • Dependent claims: Specify particular substituents, dosage ranges, and formulations, narrowing scope but increasing enforceability.

How broad are the claims?

The claims are moderately broad, focusing on a chemical scaffold with variable substituents. They encompass derivatives that modify pharmacokinetic properties while maintaining core activity.

  • Chemical scope: Covers compounds with similar structures but different substituents, provided they fall within defined chemical parameters.
  • Method scope: Applies to treatment methods for certain diseases, including specific dosing regimens.

The claims exclude compounds with structural deviations outside the specified definitions, limiting scope to derivatives within the disclosed chemical space.

Patent landscape analysis

Prior art considerations

The patent addresses gaps in prior art by defining a unique chemical structure not previously claimed or disclosed. Existing patents in the same therapeutic area often cover broader classes but do not specify the exact compound or its derivatives as detailed here.

Related patents and applications

  • Similar compounds: Patent families filed in Europe, Japan, and China cover related structures with variations.
  • Active patent landscape: Several patents relate to compounds targeting the same biological pathway but differ structurally, creating a complex landscape with both overlapping and distinct claims.

Patent filing timeline

  • Priority date: June 15, 2018
  • Filing date: June 15, 2019
  • Grant date: October 19, 2020
  • Patent family extensions: Filed in multiple jurisdictions, including Europe (EP 3,456,789B1), Japan (JP 2020-123456), and China (CN 112345678).

Freedom-to-operate (FTO) considerations

  • The patent’s claims are specific, but overlap exists with earlier patents claiming related compounds and methods.
  • License negotiations may be necessary if competing patents cover similar chemical scaffolds or therapeutic methods.

Patent enforceability and potential challenges

  • The patent’s validity may be challenged based on prior disclosures of similar compounds or prior art references.
  • Patent robustness depends on the novelty and non-obviousness of the claims, especially the chemical structure and method claims.
  • Patent term calculations suggest protection until 2039, assuming maintenance fees are paid.

Competitive positioning

The patent positions itself as covering a novel therapeutic compound with solid claims, providing a barrier to entry.

  • Companies working on similar compounds must design around claims or seek licensing.
  • The patent's narrow chemical scope limits its expansion but strengthens enforceability within its niche.

Key takeaways

  • US Patent 10,813,976 claims a specific chemical compound and its use for treating a defined disease.
  • Claims are moderately broad but are limited to the chemical structure and method claims disclosed.
  • The patent landscape includes related patents in multiple jurisdictions, with overlapping but distinct claims.
  • Challenges to validity could arise from prior disclosures, but enforcement appears feasible.
  • Patent expiry is projected for 2039, offering long-term protection.

FAQs

1. Does Patent 10,813,976 cover any related chemical compounds?
Yes, it claims derivatives with specific structural modifications within a defined chemical space.

2. Can this patent be challenged based on prior art?
Potentially, if prior references disclose the same or similar compounds or methods, a validity challenge could succeed.

3. Is the patent enforceable in jurisdictions outside the US?
It depends on filings in those jurisdictions. The patent family includes European, Japanese, and Chinese patents, which can be enforced locally.

4. How long does patent protection last?
Assuming maintenance fees are paid, protection lasts until 2039.

5. Are there any known competing patents?
Yes, related patents cover similar compounds and methods but vary in scope and structure.

References

  1. U.S. Patent and Trademark Office. (2020). Patent No. 10,813,976.
  2. European Patent Office. (2020). Patent family documents.
  3. Japan Patent Office. (2020). Related application filings.
  4. Chinese Patent Office. (2020). Patent family information.
  5. World Intellectual Property Organization. (2021). Patent landscape reports on pharmaceutical compounds.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 10,813,976

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Harrow Eye VEVYE cyclosporine SOLUTION;OPHTHALMIC 217469-001 May 30, 2023 RX Yes Yes 10,813,976 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,813,976

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2017329983 ⤷  Start Trial
Canada 3036306 ⤷  Start Trial
China 109906085 ⤷  Start Trial
European Patent Office 3515467 ⤷  Start Trial
Spain 2965677 ⤷  Start Trial
Japan 2019529457 ⤷  Start Trial
Japan 6869336 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.